GSK vs Pfizer vs Merck & Co. and 2 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: GSK 10.595, Pfizer 15.034, Merck & Co. 16.607, Sanofi 13.284, Moderna 0.145.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, GSK, Pfizer, Merck & Co., Sanofi, Moderna.| Metric | GSK | Pfizer | Merck & Co. | Sanofi | Moderna |
|---|---|---|---|---|---|
| Market Cap | $105.97B | $161.04B | $375.58B | $109.81B | $69.62B |
| Revenue | $10.60B | $15.03B | $16.61B | $13.28B | $145.00M |
| Cost of Revenue | $2.85B | $4.09B | $4.39B | $3.26B | $93.00M |
| Gross Profit | $7.74B | $10.94B | $12.21B | $10.03B | $52.00M |
| Operating Income | $606.00M | $4.71B | $-683.00M | $2.58B | $-815.00M |
| Net Income | $548.00M | $-246.00M | $-1.33B | $370.00M | $-782.00M |
| R&D Expense | $4.37B | $2.81B | $9.74B | $2.41B | $651.00M |
| Earnings Per Share | $0.28 | -$0.04 | -$0.54 | $0.15 | -$1.96 |
| Gross Margin | 73.0% | 72.8% | 73.5% | 75.5% | 35.9% |
| Operating Margin | 5.7% | 31.3% | -4.1% | 19.4% | -562.1% |
| Net Profit Margin | 5.2% | -1.6% | -8.0% | 2.8% | -539.3% |
| Free Cash Flow | $2.78B | $302.00M | $4.48B | $4.22B | $-563.00M |
| Cumulative Free Cash Flow | $157.21B | $356.70B | $249.70B | $51.81B | $7.37B |
| Operating Cash Flow | $3.19B | $835.00M | $5.37B | $5.85B | $-526.00M |
| Cash & Equivalents | $3.89B | $976.00M | $6.85B | $6.86B | $1.72B |